创建一个数字方法来促进儿童肺高血压的身体活动:未来干预措施的框架
Catherine M Avitabile1,2, Jena P Mota2, Kiley M Yeaman3
1Department of Pediatrics, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA.
Pulmonary circulation
|July 4, 2024
概括
这项试点研究探讨了为期16周的家庭炼计划,用于患有肺高血压 (PH) 的儿童. 该干预使用可穿戴技术和数字平台来提高运动能力,并评估儿科PH患者的可行性.
科学领域:
- 儿童心脏病学 儿童心脏病学
- 运动生理学 运动生理学
- 数字健康数字健康
背景情况:
- 患有肺高血压 (PH) 的儿童表现出运动能力降低,影响生活质量.
- 虽然运动对PH的成年人有好处,但最佳的儿科运动计划仍未确定.
- 肌肉缺陷导致儿科PH的运动限制.
研究的目的:
- 确定为小儿PH进行为期16周的家庭运动干预措施的可行性和初步疗效.
- 评估可穿戴技术和数字平台在儿科PH运动干预中的作用.
- 为了生成数据用于未来的,更大规模的关于青少年心肺呼吸系统疾病的运动研究.
主要方法:
- 前性,单臂,非随机试点研究.
- 家庭炼干预针对下肢肌肉质量,通过可穿戴的移动健康技术进行丰富.
- 包括量身定制的炼处方,间隔目标设定,实时活动监控和数字通信平台.
主要成果:
- 这项研究成功地使用数字健康工具为儿科PH实施了基于家庭的运动干预.
- 初步数据表明该干预措施的可行性和潜在有效性.
- 收集了有关在家进行卫生保健干预所需的数字基础设施的信息.
结论:
- 使用可穿戴技术进行为期16周的家庭炼干预对于儿科PH来说是可行的.
- 这种方法有望改善患有慢性心肺呼吸系统疾病的年轻人炼能力.
- 需要进一步的研究来证实疗效和优化儿童PH的干预措施.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
195
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
195
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
Pulmonary Hypertension: Classification and Pathogenesis
167
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
167
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
144
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
144
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
Chronic Obstructive Pulmonary Disease-V: Nursing Management
3.8K
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Assessment
3.8K


